Aktiver Javascript i din nettleser for en bedre opplevelse på regjeringen.no

NOU 1997: 6

Rammevilkår for omsetning av legemidler

Til innholdsfortegnelse

2 Referanser

AVORN J, CHEN M, HARTLEY R (1982): Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 73: 4-8

BARON D (1995): The economics and politics of regulation: Perspectives, agenda, and approaches. Modern political economy: Old topics, new directions. Edited by Banks JS & Hanushek EA, Cambridge University Press

CAVES RE, WHINSTON MD, HURWITZ MA (1991): Patent expiration, entry, and competition in the U.S. pharmaceutical industry. Brookings Paper in Economic Activity, Microeconomics, 1-48.

DALEN DM (1996): Markedet for legemidler: forskjellige priser for samme vare? Arbeidsnotat 47/96, SNF-Oslo.

DALEN DM, VISLIE J (1996): Diagnostisering og legemiddelforskrivning: gir dagens refusjonsordning legene tilstrekkelige insentiver? Upublisert notat, SNF-Oslo.

DALEN DM, VISLIE J (1997): Konkurranseforhold, etablering og distribusjon i markedet for legemidler. Rapport 1/97, SNF-Oslo.

DASGUPTA R, ZAMMIT-LUCIA J (1995): Reference pricing; the european experience. Health Policy Review Paper no. 10, St. Mary's Hospital Medical School, University of London

DAVIDSON RA (1986): Source of funding and outcome of clinical trials. J Gen Intern Med 1986; 1; 155-158

ECON SENTER FOR ØKONOMISK ANALYSE (1996): Innovasjon og utvikling i legemiddelindustrien. Rapport 54/96

ECON SENTER FOR ØKONOMISK ANALYSE (1996): Rentabilitet i apoteknæringen. notat 42/96

ECON SENTER FOR ØKONOMISK ANALYSE (1996): Resultater og lønnsomhet i apoteknæringen. Rapport 30/96

ENTHOVEN AC (1993): The history and principles of managed competition. Health Affairs, Volume 12, Supplement 1993

EVANS RG (1994): Introduction in: why are some people healthy and others not? The Derminants of Health of Populations. Edited by RG Evans, ML Barerand TR Marmor. Aldine de Gruyter, New York.

EVANS RG, BARER ML, STODDART GL (1993): User fees for health care: why a bad idea keeps coming back? Health Policy Research Unit discussion paper #93-9D. University of British Columbia, Vancouver.

FORENINGEN AV DANSKE MEDICINFABRIKKER (MEFA) (1996): Tal og data 1996; Medicin og sundhetsvæsen

FRANK RG, SALKEVER DS (1992): Pricing, patent loss and the market for pharmaceuticals. Southern Economic Journal, 59, 165-179.

FUCHS VR (1993): The future of health policy. Harvard University Press

FYLKESNES K (1991). Factors affecting self-evaluated general health status - and the use of professional health services. Institute of Community Medicine, Tromso.

FYLKESNES K (1993). Determinants of health care utilization - visits and referrals. Scand J Soc Med 21: 40-50.

FYLKESNES K, JOHNSEN R, FØRDE OH (1992): The Tromsø study: factors affecting patient-initiated and provider-initiated use of health care services. Soc Health Illness 14: 275-292.

GERDTHAM UG, JÖNSSON B (1993): Läkemedelsförmånen

GJEMS-ONSTAD O (1996): Personlig selskap vs. aksjeselskap. Upublisert notat, Handelshøyskolen BI.

GRABOWSKI HG, VERNON J (1992): Brand loyality, entry, and price competition in pharmaceuticals after the 1984 drug act. Journal of Law & Economics, 35, 331-350.

HERXHEIMER A, LUNDBORG CS, WESTERHOLM B (1993). Advertisements for medicines in leading medical journals in 18 countries: a 12-month survey of information content and standards. Int J Health Serv 23: 161-72.

HODGES B (1995): Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. Canadian Medical Association Journal, 153, 553-559.

HORN SD, SHARKEY PD, TRACY DM, HORN CE, BLAIR J, GOODWIN F (1996): Intended and unintended consequences of HMO cost-containment strategies: results from the managed care outcomes project. The American Journal of Managed Care, 1996: 2: 253-264

JAMES BG (1994): The pharmaceutical industry in 2000, The Economist Intelligence Unit (EIU)

JOHANSEN M (1993): Undersøkelse av legemidlers effektive patenttid i Norge i perioden 1970-91. Norges Apotekerforenings Tidsskrift Nr 5/93.

KLEPPER G (1995): Pharmaceuticals. In P. Buigues, A. Jacquemin og A. Sapir (red.): European policies on competition, trade industry. Edward Elgar

KOKTEVEDGAARD M (1996): Lærebog i immaterialret, 4 udg, København med videre henvisninger.

KONKURRANSETILSYNET (1995): Rapport om virkningene av pris- og avanseomleggingene på legemidler 1. januar 1995

KRISTIANSEN IS (1996): Forholdet mellom leger og legemiddelindustri. Upublisert rapport, Statens institutt for folkehelse.

KRISTIANSEN IS (1996): Lege- og pasient-insentiver i legemiddelpolitikken. Upublisert rapport, Statens institutt for folkehelse.

KRISTIANSEN IS, HJORTDAHL P (1992): The general practitioner and laboratory utilization: Why does it vary? Fam Pract 9: 22-27.

LE GRAND J, ROBINSON R (1994): Evaluating the NHS reforms, King's Fund Institute

LEGEMIDDELINDUSTRIFORENINGEN (1996): Legemidler og helsevesen, tall og fakta 1996

LEXCHIN J, HOLBROOK A (1994). Methodological quality and relevance of references in pharmaceutical advertisements in a Canadian medical journal. Can Med Assoc J 151: 47-54.

LEXCHIN J. (1993): Interactions between physicians and the pharmaceutical industry: What does the literature say? Canadian Medical Association Journal, 149, 1401-1407.

LOHR KN, BROOK RH, KAMBERG CJ (1986): Executive summary results, conclusions, and discussion. Med Care 24 Supplement: s72-s87.

LOSSIUS PT, STENVIK A (1996): Patenter på legemidler i en samfunnsmessig sammenheng. Upublisert rapport, Patentstyret

MARGOLIS LH (1991). The ethics of accepting gifts from pharmaceutical companies. Pediatrics 88: 1233-7.

NOU 1979: 26 Apotekdriftens organisasjon og funksjoner

OLUFSEN R (1996): IIR-konferanse om salg, distribusjon og markedsføring av legemidler februar 1996

PALMISANO P, EDELSTEIN J (1980): Teaching drug promotion abuses to health profession students. J Med Educ 55: 453-5.

PEDERSEN U (1994): Effektivitetskostnader ved beskatning, SNF-rapport nr. 26

ROZEK RP, RAPP RT (1995): Parallell trade in pharmaceuticals: The impact on welfare and innovation. Upublisert notat fra National Economic Research Associates Inc. (NERA)

SCHERER FM (1993): Pricing, profits, and technological progress in the pharmaceutical Industry. The Journal of Economic Perspectives, 7, 97-115.

SCRIP (1989), 1455, s 4 (Rubinstein og Goulbourne)

SMISETH OA, HORGEN E, ESKERUD J, MELSOM H (1996): Legers mening om medikamentell blodtrykksbehandling; En spørreundersøkelse i Hordaland Fylke. Tidsskr. Nor. Lægeforen. Nr. 13, 1996: 116: 1588-90

SPENCE M (1977): Consumer misperceptions, product failure, and producer liability. Review of Economic Studies, 44, 561-572.

STATENS BEREDNING FÖR UTVÄRDERING AV MEDICINSK METODIK (SBU) (1994): Måttligt förhöjt blodtryck, SBU-rapport nr. 121

STORTINGSMELDING nr. 41 (1987-88): Helsepolitikken mot år 2000

STORTINGSMELDING nr. 8 (1990-91): Om bioteknologi

STORTINGSPROPOSISJON nr. 1 (1995-96), Sosial- og helsedepartementet

STORTINGSPROPOSISJON nr. 1 (1996-97), Sosial- og helsedepartementet

STRØM S, VISLIE J (1995): Det norske markedet for legemidler. Notat, Sosialøkonomisk institutt, Universitetet i Oslo.

TIROLE J (1988): The theory of industrial organization. MIT Press.

VAN DER STICHELE RM (1994): How to influence prescribing by primary care physicians? European Symposium on Pharmoeconomics, Gent.

VISLIE J (1996): Argumenter for friere etablering i apoteksektoren. Eller kan tilsvarende virkninger oppnås på andre måter? Upublisert notat, SNF-OSLO.

WILKES MS, DOBLIN BH, SHAPIRO MF (1992): Pharmaceutical advertisements in leading medical journals: experts' assessments. Ann Intern Med 116: 912-9.

Til toppen
Til dokumentets forside